Despite the commonness of bladder cancer and its high cost to treat, little has changed in the standard of care in 40 years. We recognize the urgency to advance science and develop innovative, bladder-sparing treatment options to redefine what a bladder cancer diagnosis means for patients. Within bladder cancer, we are exploring how a personalized and targeted approach to care could transform patient outcomes long term.
Bladder cancer impacts more than 1 million people worldwide annually, including those who are newly diagnosed or facing a recurrence.”
Our differentiated program is evaluating potential treatments across all stages of the disease, including both combination and monotherapies using various drug delivery approaches, from oral dosing to our innovative intravesical drug releasing system. This system provides a potentially best-in-class platform to create comprehensive and transformative early bladder cancer regimens against a broad range of targets.
Types of bladder cancer
Non-muscle invasive bladder cancer (NMIBC)
- Cancer cells are found in the inner lining of the bladder, or within loose connective tissue below this inner layer, but have not grown into the muscle layer of the bladder wall.
- Accounts for approximately 75% of new cases.
Muscle-invasive bladder cancer (MIBC)
- Tumors invaded the bladder muscle with or without lymph node involvement.
- Accounts for approximately 20% of new cases.
Advanced and metastatic urothelial cancer (mUC)
- Locally advanced tumors may have spread to nearby organs and include tumors that have disseminated to distant organs such as the lungs or liver, or to bones.
- Accounts for approximately 5% of new cases.
Bladder cancer by the numbers
- Tenth most common cancer globally
- Impacts more than 1 million people worldwide annually, including those who are newly diagnosed or facing a recurrence
- Sixth most commonly occurring cancer in men
